| Date | Title | Description |
| 03.10.2025 | National Psoriasis Foundation Raises $235K at Inaugural New England Soirée Honoring Champions of Psoriatic Disease Care | BOSTON, MA, UNITED STATES, October 2, 2025 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) celebrated an inspiring evening at the inaugural New England Soirée on Thursday, September 18 at The Newbury Boston. The elegant gather... |
| 30.09.2025 | National Psoriasis Foundation to Host Second Annual Indy Soirée Honoring Local Health Care Leaders | INDIANAPOLIS, IN, UNITED STATES, September 30, 2025 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) will host its second annual Indy Soirée on November 13 at The Hawthorns Golf and Country Club. This vibrant evening blends dis... |
| 19.09.2025 | The National Psoriasis Foundation Applauds House Leaders for Introducing the "Safe Step Act" | ALEXANDRIA, VA, UNITED STATES, September 19, 2025 /EINPresswire.com/ -- Bipartisan Legislation Places Commonsense Guardrails On Step Therapy, Supporting 160 Million Americans Living with Chronic Conditions
September 19, 2025 - Alexandria, V... |
| 16.09.2025 | NPF Invites Columbus, Ohio to Take ACTION for Psoriatic Disease | COLUMBUS, OH, UNITED STATES, September 16, 2025 /EINPresswire.com/ -- Each year, the National Psoriasis Foundation (NPF) invites individuals impacted by psoriasis and psoriatic arthritis to join Take ACTION for Psoriatic Disease — a nationw... |
| 16.09.2025 | NPF Invites New York to Take ACTION for Psoriatic Disease | NEW YORK, NY, UNITED STATES, September 16, 2025 /EINPresswire.com/ -- Each year, the National Psoriasis Foundation (NPF) invites individuals impacted by psoriasis and psoriatic arthritis to join Take ACTION for Psoriatic Disease—a nationwid... |
| 16.09.2025 | NPF Invites Fort Worth to Take ACTION for Psoriatic Disease | FORT WORTH, TX, UNITED STATES, September 16, 2025 /EINPresswire.com/ -- Each year, the National Psoriasis Foundation (NPF) invites individuals impacted by psoriasis and psoriatic arthritis to join Take ACTION for Psoriatic Disease — a natio... |
| 11.09.2025 | National Psoriasis Foundation Announces 2026 National Gala Honorees | ALEXANDRIA, VA, UNITED STATES, September 11, 2025 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) will host its flagship annual celebration and largest fundraising initiative, the Commit to Cure Gala, in Salt Lake City in 2026... |
| 09.09.2025 | NPF Invites Philadelphia to Take ACTION for Psoriatic Disease | PHILADELPHIA, PA, UNITED STATES, September 9, 2025 /EINPresswire.com/ -- Each year, the National Psoriasis Foundation (NPF) invites individuals impacted by psoriasis and psoriatic arthritis to join Take ACTION for Psoriatic Disease — a nati... |
| 09.09.2025 | NPF Invites Chicago to Take ACTION for Psoriatic Disease | CHICAGO, IL, UNITED STATES, September 9, 2025 /EINPresswire.com/ -- Each year, the National Psoriasis Foundation (NPF) invites individuals impacted by psoriasis and psoriatic arthritis to join Take ACTION for Psoriatic Disease — a nationwid... |
| 26.08.2025 | National Psoriasis Foundation Announces Total Body Wellness Day | Celebrating head to toe wellbeing on August 26. ALEXANDRIA, VA, UNITED STATES, August 26, 2025 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) is proud to announce the first ever Total Body Wellness Day on August 26, 2025. Thi... |
| 21.08.2025 | National Psoriasis Foundation Announces 2025 Grant and Fellowship Awards | ALEXANDRIA, VA, UNITED STATES, August 21, 2025 /EINPresswire.com/ -- The National Psoriasis Foundation – the worldwide nonprofit leader in psoriatic disease research funding – is pleased to announce its continued support of high-quality res... |
| 18.08.2025 | National Psoriasis Foundation to Host Inaugural New England Soirée Honoring Champions of Psoriatic Disease Care | BOSTON, MA, UNITED STATES, August 18, 2025 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) will host the inaugural New England Soirée on Thursday, September 18 at The Newbury Boston, an elegant evening dedicated to raising cri... |
| 01.08.2025 | National Psoriasis Foundation Launches Psoriasis Action Month 2025: 'This is Psoriasis – Total Wellness' | August Campaign Highlights Total Wellness for Over 8 Million in the U.S. with Psoriasis ALEXANDRIA, VA, UNITED STATES, August 1, 2025 /EINPresswire.com/ -- Embracing Total Wellness for the Psoriasis Community
This August, the National Psori... |
| 24.07.2025 | NPF Raises $1.5 Million to Transform the Lives of People with Psoriatic Disease | From left to right: Dr. Joel Gelfand, Leah Howard, J.D., Carol Ostrow, Dr. Jose Scher ALEXANDRIA, VA, UNITED STATES, July 24, 2025 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) Commit to Cure Gala raised more than $1.5 milli... |
| 18.06.2025 | SciBase and Castle Biosciences: A New Era in Dermatological Diagnostics | In the world of dermatology, innovation is the lifeblood that keeps the field thriving. Recently, SciBase Holding AB, a Swedish medical technology company, made waves by signing a collaboration and license agreement with Castle Biosciences,... |
| 17.06.2025 | Making Home Light Therapy Accessible | Following publication of the novel LITE clinical trial results, NPF and Elevance Health partner to make home-based phototherapy accessible. ALEXANDRIA, VA, UNITED STATES, June 17, 2025 /EINPresswire.com/ -- Informed by data and recommendati... |
| 16.06.2025 | SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30 | SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30
Mon, Jun 16, 2025 22:30 CET Report this... |
| 20.03.2025 | National Psoriasis Foundation Offers People with Psoriasis a Way to cōpe | ALEXANDRIA, VA, UNITED STATES, March 20, 2025 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) is pleased to announce a special offer made possible by our relationship with cōpe, an online community providing extra guidance and... |
| 03.03.2025 | NPF Partners with Boehringer Ingelheim to Launch a New Campaign to Increase Awareness of Generalized Pustular Psoriasis | ALEXANDRIA, VA, UNITED STATES, March 3, 2025 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) is excited to announce the launch of a new campaign to provide education on Generalized Pustular Psoriasis (GPP). GPP, also known as ... |
| 04.02.2025 | Advancing Cardiovascular Care for Individuals with Psoriatic Disease | ALEXANDRIA, VA, UNITED STATES, February 4, 2025 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) is pleased to announce an anonymous gift of up to 1 million dollars that will strengthen NPF’s approach to preventing cardiovascul... |
| 28.10.2024 | Birmingham is Ready to Take ACTION for Psoriatic Disease | BIRMINGHAM, AL, UNITED STATES, October 28, 2024 /EINPresswire.com/ -- Each year, the National Psoriasis Foundation (NPF) invites the community of people impacted by psoriasis and psoriatic arthritis to join Take ACTION for Psoriatic Disease... |
| 25.10.2024 | D.C. is Ready to Take ACTION for Psoriatic Disease | ALEXANDRIA, VA, UNITED STATES, October 25, 2024 /EINPresswire.com/ -- Each year, the National Psoriasis Foundation (NPF) invites the community of people impacted by psoriasis and psoriatic arthritis to join Take ACTION for Psoriatic Disease... |
| 10.10.2024 | NPF’s Journal of Psoriasis and Psoriatic Arthritis Receives PubMed Indexing | ALEXANDRIA, VA, UNITED STATES, October 10, 2024 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) is pleased to announce that because of its excellence in research publication, the Journal of Psoriasis and Psoriatic Arthritis® (... |
| 30.09.2024 | Columbus, Ohio Ready to Take ACTION for Psoriatic Disease | COLUMBUS, OH, UNITED STATES, September 30, 2024 /EINPresswire.com/ -- Each year, the National Psoriasis Foundation (NPF) invites the community of people impacted by psoriasis and psoriatic arthritis to join Take ACTION for Psoriatic Disease... |
| 30.09.2024 | Portland, Oregon Set to Take ACTION for Psoriatic Disease | PORTLAND, OR, UNITED STATES, September 30, 2024 /EINPresswire.com/ -- Each year, the National Psoriasis Foundation (NPF) invites the community of people impacted by psoriasis and psoriatic arthritis to join Take ACTION for Psoriatic Disease... |
| 16.09.2024 | Chicago Community Set to Take ACTION for Psoriatic Disease | CHICAGO, IL, UNITED STATES, September 16, 2024 /EINPresswire.com/ -- Each year, the National Psoriasis Foundation (NPF) invites the community of people impacted by psoriasis and psoriatic arthritis to join Take ACTION for Psoriatic Disease ... |
| 16.09.2024 | Take ACTION for Psoriatic Disease in Philadelphia | PHILADELPHIA, PA, UNITED STATES, September 16, 2024 /EINPresswire.com/ -- Each year, the National Psoriasis Foundation (NPF) invites the community of people impacted by psoriasis and psoriatic arthritis to join Take ACTION for Psoriatic Dis... |
| 29.08.2024 | How Psoriasis Stigma Impacts Health | (National Psoriasis Foundation) - You’ve seen the commercials. Psoriasis treatments are everywhere. So it would follow that people with psoriasis can also be found everywhere, right? In theory, yes. About 3 percent of all people will develo... |
| 20.08.2024 | New Report Reveals Widespread Stigma of Psoriasis May Be Contributing to Dangerous Delays in Care | During National Psoriasis Action Month, National Psoriasis Foundation Warns Lack of Awareness May Put Millions at Risk for Chronic Health Conditions ALEXANDRIA, VIRGINIA, UNITED STATES, August 20, 2024 /EINPresswire.com/ -- Today, the Natio... |
| 15.08.2024 | NPF Publishes Comprehensive Psoriasis Health Indicator Report | ALEXANDRIA, VIRGINIA, UNITED STATES, August 15, 2024 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) is pleased to announce the release of the first published report about the health impacts of psoriasis. The Psoriasis Health ... |
| 01.08.2024 | Take ACTION for Psoriatic Disease During Psoriasis Action Month | NPF unites the psoriatic disease community while raising critical funds. ALEXANDRIA, VIRGINIA, UNITED STATES, August 1, 2024 /EINPresswire.com/ -- August is Psoriasis Action Month, and the National Psoriasis Foundation (NPF) has launched th... |
| 08.07.2024 | Research for a Cure: 2024 NPF Grant and Fellowship Awards | The National Psoriasis Foundation announces their annual research grants and fellowships. ALEXANDRIA, VA, UNITED STATES, July 8, 2024 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) – the worldwide nonprofit leader in psoriati... |
| 26.05.2024 | Stress and Skin: A Complex Relationship | Stress can be a silent killer, not just for your mental health but also for your skin. Dermatologists reveal the hidden connection between stress and skin problems, shedding light on how our emotions can manifest physically.
Stress is like ... |
| 20.05.2024 | Studies Show Linked Biological Pathways Driving Skin Inflammation | NEW YORK, May 20, 2024 /PRNewswire/ -- A certain biological pathway, a set of linked reactions in the body, drives the inflammation seen in the skin disease psoriasis, a new study finds. The work could lead to improved therapies for all inf... |
| 14.05.2024 | Zerigo Health and Nextiva Partner to Expand Benefits for Employees with Chronic Skin Conditions | Connected Communications company now offers employees with psoriasis, eczema, and vitiligo a proven, at-home phototherapy treatment option
Offering Zerigo’s Skin Health Platform as part of our already robust benefit plans enables us to prov... |
| 01.05.2024 | US FDA approves high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm) injection, Boehringer Ingelheim's interchangeable* biosimilar to Humira® | RIDGEFIELD, Conn., May 1, 2024 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), the company's ... |
| 01.05.2024 | PsA Action Month Launches Today | National Psoriasis Foundation honors all those impacted by psoriatic arthritis during PsA Action Month. ALEXANDRIA, VA, UNITED STATES, May 1, 2024 /EINPresswire.com/ -- Each May the National Psoriasis Foundation (NPF) leads the charge to re... |
| 09.03.2024 | The Light Treatment Effectiveness (LITE) Study Reveals Groundbreaking Data on the Effectiveness of Phototherapy | Research Demonstrates that Home Phototherapy is Non-Inferior to Office Phototherapy, with Excellent Effectiveness and Safety in Real World Settings ALEXANDRIA, VA, UNITED STATES, March 9, 2024 /EINPresswire.com/ -- Groundbreaking data prese... |
| 31.01.2024 | NPF and IPC Publish Findings on Psoriasis Location Impacting Patient Quality of Life | The International Psoriasis Council and National Psoriasis Foundation publish findings on psoriasis severity assessment with respect to special locations. ALEXANDRIA, VA, UNITED STATES, January 31, 2024 /EINPresswire.com/ -- The longtime st... |
| 03.08.2023 | How can you tell if your itchy rash is psoriasis and not eczema? What are the treatments available? | Mention “psoriasis” and many people would draw a blank or, at best, mistake it for eczema. And it is an easy mistake to make as the dry rashes of both skin conditions may appear similar.
But look closer and you’ll see that the affected area... |
| 02.09.2022 | Portland Area Runners: Run with Jesse | Writer and film producer Jesse Lichtenstein is tackling serious mileage to cure psoriatic disease, and you can join in the fun. PORTLAND, OR, UNITED STATES, September 2, 2022 /EINPresswire.com/ -- With his Chicago Marathon debut only 5 week... |
| 03.12.2021 | Johnson & Johnson : Latest Phase 3 Data for First-in-Class TREMFYA® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintain... | SPRING HOUSE, PENNSYLVANIA, December 3, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheuma... |
| 29.10.2021 | MotherToBaby to Share Pregnancy, Breastfeeding Resources on World Psoriasis Day | The goal of our study is to gather information from pregnant people with psoriatic disease so we can better understand whether or not medications they are already taking may affect their pregnancy or their developing baby.
LA JOLLA, Calif. ... |
| 28.10.2021 | Almirall launches "Shedding Light on Psoriasis" campaign to raise awareness on World Psoriasis Day | Almirall launches "Shedding Light on Psoriasis" campaign to raise awareness on World Psoriasis Day 28 October 2021
The campaign aims to raise awareness on how psoriasis deeply impacts the wellbeing of people living with this long-... |
| 21.09.2021 | FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis | RALEIGH, N.C., Sept. 21, 2021 /PRNewswire/ -- Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in adolescents.
LEXETTE, a super potent to... |
| 17.08.2021 | Novartis : secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis | China National Medical Products Administration (NMPA) approval reinforces that Cosentyx® (secukinumab) is safe and effective for children and adults with psoriasis
Moderate-to-severe plaque psoriasis affects more than 350,000 children world... |
| 19.07.2021 | EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) | CHARLESTON, S.C. and COPENHAGEN, Denmark, July 19, 2021 /PRNewswire/ -- EPI Health and MC2 Therapeutics, announced today commercial availability in the United States of Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005... |
| 25.06.2021 | UCB : Receives Positive CHMP Opinion Recommending Approval of BIMZELX (bimekizumab … | · The positive CHMP opinion is supported by data from three Phase 3 studies where bimekizumab demonstrated superior levels of skin clearance compared to placebo, ustekinumab and adalimumab
· If approved by the European Commission, bimekizum... |
| 11.06.2021 | 5 common causes of an itchy scalp and how to treat it, according to dermatologists | An itchy scalp is usually harmless, but it can be uncomfortable and even painful. nebari/Getty Images
Common causes of an itchy scalp include dandruff, head lice, psoriasis, and atopic dermatitis.
To treat an itchy scalp, see a primary care... |
| 02.06.2021 | JOHNSON & JOHNSON
Johnson & Johnson : New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearan... | SPRING HOUSE, PENNSYLVANIA, June 2, 2021 - Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a... |
| 01.06.2021 | NOVARTIS AG
Press Release : Novartis Cosentyx receives FDA -2- | https://twitter.com/novartisnews https://twitter.com/novartisnews For Novartis multimedia content, please visit https://www.novartis.com/news/media-library https://www.novartis.com/news/media-library For questions about the site or required... |
| 28.04.2021 | UCB
UCB : Announces PDUFA Date for Bimekizumab | Brussels, Belgium - 28 April 2021, 7:00 CEST - UCB announced today that the U.S. Food and Drug Administration (FDA) has set the Prescription Drug User Fee Act (PDUFA) date for UCB's Biologics License Application (BLA) for bimekizumab for th... |
| 23.04.2021 | Johnson & Johnson : New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust... | SPRING HOUSE, PENNSYLVANIA, April 23, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of... |
| 23.04.2021 | JOHNSON & JOHNSON
Johnson & Johnson : New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Pso... | SPRING HOUSE, PENNSYLVANIA, April 23, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of... |
| 21.04.2021 | Bausch Health : Ortho Dermatologics to Present New Data at the 2021 American Academy of Dermatology Annual Meeting | Six Poster Presentations Will Include New Analyses on ARAZLO®, DUOBRII® and SILIQ®
LAVAL, Quebec, April 21, 2021 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatolo... |
| 21.04.2021 | BAUSCH HEALTH COMPANIES INC.
Bausch Health : Ortho Dermatologics to Present New Data at the 2021 American Academy of Dermatology Annual Meeting | Six Poster Presentations Will Include New Analyses on ARAZLO®, DUOBRII® and SILIQ®
LAVAL, Quebec, April 21, 2021 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatolo... |
| 25.11.2020 | Can You Host In-Person Events During A Pandemic? | National Psoriasis Foundation has played host to a series of socially distanced, in-person ... [+] fundraising events during COVID-19.National Psoriasis Foundation |
| 09.09.2020 | Tennis Champion Caroline Wozniacki and UCB Launch Advantage Hers Campaign for Women with Chronic Inflammatory Diseases | BRUSSELS, Belgium, Sept. 9, 2020 /PRNewswire/ -- UCB, a global biopharmaceutical company, has partnered with world-renowned tennis champion Caroline Wozniacki to launch Advantage Hers, a major new global health initiative. Inspired by Carol... |
| 01.09.2014 | Skylit’s handheld device could bring psoriasis, eczema phototherapy home | Skylit’s concept is to develop its handheld device, setting up an out-of-pocket subscription service for patients to essentially lease it and use it at home. The patient would receive a prescription from a dermatologist, and then the doctor... |
| 12.05.2014 | TVM Life Science Ventures VII Announces Investment in PRCL Research Inc. | Montréal, Québec, May 12th, 2014 –TVM Life Science Ventures VII today announced the fund’s fourth investment, a co-investment with the Fonds de solidarité FTQ (the “Fonds”) – establishing PRCL Research Inc., a company based in Montréal, Qué... |
| 13.12.2012 | Expanding tools for clinical research, rare disease network gets Sanofi award | The competition began earlier this year at the Partners in Patient Health Forum in Washington, DC. The challenge required two or more groups to collaborate in order to qualify for the contest and designed to promote sharing of complementary... |
| 07.02.2012 | Topical drug for inflammatory skin conditions banks on natural, safe profile | Therosol has also been formulated into products used to prevent radiation burns in cancer patients and relieve symptoms after certain cosmetic procedures. One of the biggest target markets for the company is pediatrics, Fuller said, because... |
| 08.11.2011 | Fluence Therapeutics looks for funding to develop new psoriasis treatment | Now, thanks to a design developed by renowned firm Nottingham Spirk that uses tiles with light-emitting diodes attached to a flexible substrate that conforms to the body, Goldenberg thinks Fluence has overcome that challenge. The company is... |
| - | A 3-step approach to equitable care in immunology | Over the past two decades, scientific innovation has translated cutting-edge science into real progress for people living with immune-mediated diseases, such as Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis.[1] How... |
| - | Topical drug for inflammatory skin conditions banks on natural, safe profile | An Oklahoma pharmaceutical skin care company thinks it has set itself apart in the crowded dermatology market with a line of safe, natural topical therapeutics for various inflammatory skin conditions that it plans on taking to a national m... |
| - | Fluence Therapeutics looks for funding to develop new psoriasis treatment | A University Hospitals Case Medical Center spinoff company is hoping to raise seed funding to develop the third-generation prototype of a device that uses near-infrared light to treat psoriasis.
Akron, Ohio-based Fluence Therapeutics is dev... |
| - | Expanding tools for clinical research, rare disease network gets Sanofi award | A patient-centric tool to provide a virtual research network for rare diseases to improve clinical trial recruitment has taken the top prize in an innovation challenge from Sanofi US.
Registries for All Diseases will get $300,000 to create ... |
| - | Skylit’s handheld device could bring psoriasis, eczema phototherapy home | San Diego startup Skylit Medical is developing a phototherapy device for private home use to treat conditions like psoriasis, eczema and vitiligo. It’s one of those necessity’s the mother of inventionish stories – founder Martyn Gross himse... |
